Remon J - Search Results

1

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.

Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD. Remon J, et al. ESMO Open. 2024 May;9(5):103004. doi: 10.1016/j.esmoop.2024.103004. Epub 2024 Apr 22. ESMO Open. 2024. PMID: 38653155 Free PMC article.

2

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

Remon J, Besse B. Remon J, et al. Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018. Front Oncol. 2018. PMID: 29696132 Free PMC article. Review.

3

The efficacy of immune checkpoint inhibitors in thoracic malignancies.

Remon J, Facchinetti F, Besse B. Remon J, et al. Eur Respir Rev. 2021 Oct 5;30(162):200387. doi: 10.1183/16000617.0387-2020. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34615702 Free PMC article. Review.

4

Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.

Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B. Bluthgen MV, et al. Among authors: remon j. Lung Cancer. 2016 Sep;99:111-6. doi: 10.1016/j.lungcan.2016.06.020. Epub 2016 Jul 1. Lung Cancer. 2016. PMID: 27565923

5

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

Remon J, Le Rhun E, Besse B. Remon J, et al. Cancer Treat Rev. 2017 Feb;53:128-137. doi: 10.1016/j.ctrv.2016.12.006. Epub 2016 Dec 30. Cancer Treat Rev. 2017. PMID: 28110254 Review.

6

Small cell lung cancer: a slightly less orphan disease after immunotherapy.

Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G, Soria JC. Remon J, et al. Ann Oncol. 2021 Jun;32(6):698-709. doi: 10.1016/j.annonc.2021.02.025. Epub 2021 Mar 15. Ann Oncol. 2021. PMID: 33737119 Free article. Review.

7

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B. Remon J, et al. Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017. Ann Oncol. 2017. PMID: 28104619 Free article. Clinical Trial.

8

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.

Benitez JC, Remon J, Besse B. Benitez JC, et al. Among authors: remon j. Clin Cancer Res. 2020 Oct 1;26(19):5068-5077. doi: 10.1158/1078-0432.CCR-19-3255. Epub 2020 May 20. Clin Cancer Res. 2020. PMID: 32434852 Review.

9

Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis.

Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M, Hochstenbag M, Hendriks LEL, Besse B. Remon J, et al. Eur J Cancer. 2023 Feb;180:117-124. doi: 10.1016/j.ejca.2022.12.005. Epub 2022 Dec 12. Eur J Cancer. 2023. PMID: 36592506 Free article.

10

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.

Tagliamento M, Di Maio M, Remon J, Bironzo P, Genova C, Facchinetti F, Aldea M, Le Péchoux C, Novello S, Barlesi F, Besse B, Planchard D. Tagliamento M, et al. Among authors: remon j. J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9. J Thorac Oncol. 2024. PMID: 37567387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

640 results

Search Page